Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's …

…, N Sheehy, Y Guo, A Dorosario, CG Sakellis… - Journal of the American …, 2013 - Elsevier
BACKGROUND: Merkel cell carcinoma (MCC) is a rare and lethal cutaneous neuroendocrine
carcinoma. Imaging is crucial for accurate staging, which remains a strong predictor of …

Pancreatitis secondary to anti–programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT

YZ Alabed, A Aghayev, C Sakellis… - Clinical Nuclear …, 2015 - journals.lww.com
A 57-year-old man with metastatic melanoma developed colitis secondary to ipilimumab, a
known immune-related adverse event (irAE). The patient then received pembrolizumab …

Role of FDG-PET/CT in extramedullary multiple myeloma: correlation of FDG-PET/CT findings with clinical outcome

SH Tirumani, C Sakellis, H Jacene… - Clinical nuclear …, 2016 - journals.lww.com
Purpose The aim of this study was to describe FDG-PET/CT findings in extramedullary
multiple myeloma (EMM) correlating them with clinical outcome. Methods In this institutional …

Gynecologic oncologic imaging with PET/CT

P Grant, C Sakellis, HA Jacene - Seminars in Nuclear Medicine, 2014 - Elsevier
FDG-PET/CT has been evaluated in a variety of gynecologic malignancies in a variety of
settings and is approved by the Centers for Medicare & Medicaid Services for the initial and …

Guidance on 177Lu-DOTATATE peptide receptor radionuclide therapy from the experience of a single nuclear medicine division

A Abbott, CG Sakellis, E Andersen… - Journal of Nuclear …, 2018 - Soc Nuclear Med
177 Lu-DOTATATE is a radiolabeled somatostatin analog that has been approved by the
US Food and Drug Administration (FDA) for the treatment of somatostatin receptor–positive …

PET/CT and Renal Pathology: A Blind Spot for Radiologists? Part 2??? Lymphoma, Leukemia, and Metastatic Disease

…, KO??? Regan, H Jacene, C Sakellis… - American Journal of …, 2012 - Am Roentgen Ray Soc
OBJECTIVE. PET/CT with 18 F-FDG is a powerful tool to evaluate patients with hematologic
malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically …

PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology

…, KO??? Regan, H Jacene, C Sakellis… - American Journal of …, 2012 - Am Roentgen Ray Soc
OBJECTIVE. PET/CT with 18 F-FDG shows metabolically active disease and is widely used
for the diagnosis and follow-up of patients with cancer. Nonmetabolically active renal …

End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis

J Pyo, K Won Kim, HA Jacene, CG Sakellis… - Clinical Cancer …, 2013 - AACR
Purpose: Use of 2[ 18 F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)
in postchemotherapy response assessment in follicular lymphoma is still a controversial …

Extraprostatic Uptake of 18F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer

MS Robertson, CG Sakellis, H Hyun… - American Journal of …, 2020 - Am Roentgen Ray Soc
OBJECTIVE. Fluciclovine is a synthetic radiolabeled amino acid analog used for imaging of
biochemical recurrent prostate cancer. Uptake of fluciclovine is mediated by several amino …

Merkel cell carcinoma: a primer for the radiologist

SH Tirumani, AB Shinagare, C Sakellis… - American Journal of …, 2013 - Am Roentgen Ray Soc
OBJECTIVE. Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine
tumor. The purpose of this review is to provide a comprehensive description of the staging, …